Increase efficiencies and productivity by automating core reporting tasks for medical writing.
Automate core regulatory report documents across the CTD pyramid and dramatically accelerate submission timelines.
Claret Capital Partners has invested €10M in Yseop to support global expansion and accelerate development of its Generative AI platform. Yseop Copilot helps leading pharma companies like Eli Lilly and Novartis create compliant regulatory documentation faster and with greater consistency.
Yseop’s first CMC-focused offering automates the Quality Overall Summary (Module 2.3), a central component of regulatory submissions that pulls structured insights from Module 3.2.
Yseop Expands into CMC: Redefining Regulatory Automation Beyond Clinical Read More »
The FDA has begun using generative AI to review drug submissions, signaling a major shift in regulatory review. Learn how this impacts pharma teams and what it takes to make your content AI-ready.
Download Yseop’s Comprehensive Guide to Workflow Automation The pharmaceutical industry is undergoing one of the most significant transformations in history with the introduction of Generative AI. Discover how the world’s largest pharmaceutical firms have accelerated drug development and significantly reduced time to market throughout the clinical trial process using AI in our latest whitepaper.
Whitepaper: Harness the Power of Generative AI in Pharma Read More »
Cognizant’s AI and industry expertise, combined with Yseop’s generative AI platform, aims to improve the productivity of scientific writers across the life sciences value chain
Already a leading provider of Generative AI for life sciences, Yseop leverages AWS for greater scalability and the acceleration of new drug introductions
See how Yseop Copilot is different from other Generative AI technologies across BioPharma and regulated industries.
Yseop Copilot vs. Alternative GenAI Technologies Read More »
Reinforcing Yseop’s unique footprint in the GenAI space for BioPharma, a new investment enables Yseop to expand the scope of its Generative AI offerings and accelerate its leadership position in life sciences.
The Promise And Challenge Of Deploying AI In Clinical Trials Read More »
Reinforcing Yseop’s unique footprint in the GenAI space for BioPharma, a new investment enables Yseop to expand the scope of its Generative AI offerings and accelerate its leadership position in life sciences.
Listen to the next episode of AI Uncovered with Gregor Mittersinker.
AI Uncovered with Gregor Mittersinker (ChatGPT & the Impact on UX and Design) Read More »